Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.

@article{Debruyne2008PlacebocontrolledDP,
  title={Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.},
  author={Frans M. J. Debruyne and Arkadij A Gres and Dmitrii L Arustamov},
  journal={European urology},
  year={2008},
  volume={54 1},
  pages={170-7}
}
BACKGROUND Pilot studies with daily dosing suggested the use of the luteinizing hormone-releasing hormone antagonist cetrorelix (CET) for the treatment of symptoms from benign prostatic hyperplasia (BPH). OBJECTIVE To assess efficacy and safety of three dosing schemes of CET in patients with symptomatic BPH. DESIGN, SETTING AND PARTICIPANTS After a run-in period with 4 weekly injections of placebo, 140 patients with an international prostate symptoms score (IPSS) > or =13 and a peak urinary… CONTINUE READING